CIK 0001228627
- Non-accelerated filer
- Smaller reporting company
Opus Genetics, Inc.
Sign in to watch- Ticker
- IRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 113516358
- Phone
- +1 984-884-6030
- Business address
- 8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 27713
- Former names
- Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,211,769
- in 7 filings, $50K under 10b5-1 plans
Net −$3,211,769. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Foundation Fighting Blindness Retinal Degeneration Fund −$2.8M Director sold 15% of stake
- Gagnon Robert E. −$177K Chief Financial Officer sold 7% of stake
- Magrath George −$145K Chief Executive Officer sold 2% of stake
- YERXA BENJAMIN R −$117K President sold 5% of stake
- SCHACHLE JOSEPH K −$17K Chief Operating Officer sold 2% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-20 | Ainsworth Sean Director | Grant or award | +24,367 | 321,692 | ||
| 2026-01-01 | Ainsworth Sean Director | Grant or award | +42,507 | 297,325 | ||
| 2025-08-25 | Ainsworth Sean Director | Grant or award | +86,956 | $1.15 | $100K | 254,818 |
| 2025-04-30 | Ainsworth Sean Director | Grant or award | +79,504 | 167,862 | ||
| 2025-04-30 | Ainsworth Sean Director | Grant or award · Stock Option (Right to Buy) | +79,592 | 79,592 | ||
| 2024-06-11 | Ainsworth Sean Director | Grant or award | +41,143 | 88,358 | ||
| 2024-06-11 | Ainsworth Sean Director | Grant or award · Stock Option (Right to Buy) | +35,181 | 35,181 | ||
| 2023-06-06 | Ainsworth Sean Director | Grant or award | +10,976 | 47,215 | ||
| 2023-06-06 | Ainsworth Sean Director | Grant or award · Stock Option | +9,639 | 9,639 | ||
| 2022-10-19 | Ainsworth Sean Director | Option exercise | +1,574 | $0.00 | $0 | 41,239 |
| 2022-10-19 | Ainsworth Sean Director | Option exercise · Series B Warrant (right to buy) | −1,574 | 0 | ||
| 2022-06-13 | Ainsworth Sean Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2021-06-07 | Ainsworth Sean Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2020-11-19 | Ainsworth Sean Director | Purchase | +8,865 | 44,665 | ||
| 2020-11-19 | Ainsworth Sean Director | Purchase · Series A Warrant (right to buy) | +13,394 | 13,394 | ||
| 2020-11-19 | Ainsworth Sean Director | Purchase · Series B Warrant (right to buy) | +1,574 | 1,574 | ||
| 2020-11-11 | Ainsworth Sean Director | Grant or award · Stock Option (right to buy) | +5,000 | 5,000 | ||
| 2020-11-05 | Ainsworth Sean Director | Grant or award | +35,800 | 35,800 | ||
| 2020-11-05 | Ainsworth Sean Director | Grant or award · Stock Option (right to buy) | +35,663 | 35,663 | ||
| 2020-11-05 | Ainsworth Sean Director | Grant or award · Stock Option (right to buy) | +52,825 | 52,825 |
Page 1 of 1 · 20 trades